

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Olanzapine

INITIATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- The patient has had an initial Special Authority approval for paliperidone depot injection or risperidone depot injection
- or
 - The patient has schizophrenia or other psychotic disorder
 - and
 - The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents
 - and
 - The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months

- and
 - The patient has trialed other funded depot antipsychotics (aripiprazole, risperidone, and paliperidone) unless it is considered clinically inappropriate to use these
- and
 - The patient continues to have difficulties with adherence on oral antipsychotic treatments
- and
 - Prescribing clinician has relevant Clinical Director (Mental Health and Addiction services) approval

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

- The initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection

I confirm that the above details are correct:

Signed: Date: